bioAffinity Technologies
BIAFW
6 hedge funds and large institutions have $137K invested in bioAffinity Technologies in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
4.05% more ownership
Funds ownership: 0% → 4.05% (+4.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$212K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$27.1K |
| 3 |
CS
Clear Street
New York
|
+$25.9K |
| 4 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$20.1K |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$13K |
Top Sellers
BIAFW Hedge Fund Activity: Q3 2022 in Review
6 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in bioAffinity Technologies (BIAFW) for Q3 2022, worth a combined $137K.
Buyers outnumbered sellers: 6 funds opened new BIAFW positions and 0 closed out — a net gain of 6 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $212K.
- 6 institutional investors held bioAffinity Technologies (BIAFW) as of Q3 2022, up from 0 in Q2 2022.
- Funds reported $137K of bioAffinity Technologies stock for Q3 2022.
- 6 funds opened new bioAffinity Technologies positions in Q3 2022 and 0 closed out, a net change of +6 holders.
- The largest bioAffinity Technologies buyer in Q3 2022 was Armistice Capital, an estimated $212K added.
Based on aggregated 13F filings for Q3 2022.